Drug Profile
Nofazinlimab - CStone Pharmaceuticals
Alternative Names: CS-1003Latest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator CStone Pharmaceuticals
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Liver cancer
- Phase I Lymphoma; Solid tumours
Most Recent Events
- 09 Nov 2023 CStone Pharmaceuticals has granted 3SBio the exclusive license rights to develop, register, produce and commercialize the anti-PD-1 monoclonal antibody nofazinlimab in mainland China
- 01 Nov 2023 CStone Pharmaceuticals and Shenyang Sunshine Pharmaceuticals entered into a licensing agreement for nofazinlimab in mainland China
- 28 Dec 2022 No recent reports of development identified for phase-I development in Lymphoma(Inoperable/Unresectable) in China (IV)